ZEINA A NAHLEH

Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology EL PASO, TX NPI 1790742476

General Payments — all program years on this page

$2,043.17

  • Category: General Payments
  • Program years: PY2019–2024
  • Record count: 58
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $381.13 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $381.1319

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2019 $539.413
2020 $500.001
2021 $67.245
2022 $292.2715
2023 $263.1215
2024 $381.1319

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087079720 Novartis Pharmaceuticals Corporation $16.61 03/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087079738 Novartis Pharmaceuticals Corporation $13.18 06/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087079748 Novartis Pharmaceuticals Corporation $20.28 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1089461257 Daiichi Sankyo Inc. $18.86 03/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104526890 AstraZeneca Pharmaceuticals LP $20.22 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104743269 AstraZeneca Pharmaceuticals LP $16.69 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104752998 AstraZeneca Pharmaceuticals LP $31.30 04/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105509788 AstraZeneca Pharmaceuticals LP $24.62 06/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116382070 GlaxoSmithKline, LLC. $16.54 11/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116501915 GlaxoSmithKline, LLC. $22.56 07/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116657417 GlaxoSmithKline, LLC. $18.38 09/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131305918 PFIZER INC. $16.24 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141432387 SOBI, INC $20.02 05/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141747386 Merck Sharp & Dohme LLC $18.30 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142966158 Stemline Therapeutics Inc. $23.13 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144719390 TerSera Therapeutics LLC $24.20 09/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144963738 Takeda Pharmaceuticals U.S.A., Inc. $20.39 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150170516 Tempus AI, Inc $21.21 11/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1152536901 Myriad Genetic Laboratories, Inc. $18.40 12/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.